Australia's Zelira climbs on funding for HOPE 1's FDA trials

Zelira Therapeutics

22/05/2023 06:17

** Shares of Zelira Therapeutics  ZLD.AX  rise as much as
4.4% to A$0.95, hitting its highest since May 4
    ** Biopharma co says it has got additional funding of $3.25
mln from Forman Family Foundation to support the FDA clinical
trials for its HOPE 1 product 
    ** Co says it will continue to raise up to an additional $22
mln to complete funding for the trials in autism
    ** Stock has fallen 9% so far this year, as of last close

 (Reporting by Navya Mittal in Bengaluru)
 ((navya.mittal@thomsonreuters.com))